Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

被引：133

作者：

Hamid, Omid ^{[1
]}

Robert, Caroline ^{[2
,3
]}

Ribas, Antoni ^{[4
]}

Hodi, F. Stephen ^{[5
]}

Walpole, Euan ^{[6
]}

Daud, Adil ^{[7
]}

Arance, Ana S. ^{[8
]}

Brown, Ewan ^{[9
,10
]}

Hoeller, Christoph ^{[11
]}

Mortier, Laurent ^{[12
]}

Schachter, Jacob ^{[13
]}

Long, Jianmin ^{[14
]}

Ebbinghaus, Scot ^{[14
]}

Ibrahim, Nageatte ^{[14
]}

Butler, Marcus ^{[15
]}

机构：

[1] Angeles Clin & Res Inst, Los Angeles, CA 90025 USA

[2] Gustave Roussy, Villejuif, France

[3] Paris Sud Univ, Villejuif, France

[4] Univ Calif Los Angeles, Los Angeles, CA USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Princess Alexandra Hosp, Brisbane, Qld, Australia

[7] Univ Calif San Francisco, San Francisco, CA 94143 USA

[8] Hosp Clin Barcelona, Barcelona, Spain

[9] Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland

[10] Western Gen Hosp, Edinburgh, Midlothian, Scotland

[11] Med Univ Vienna, Vienna, Austria

[12] Univ Lille, CHRU Lille, Lille, France

[13] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Tel Hashomer, Israel

[14] Merck & Co Inc, Kenilworth, NJ USA

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

BRITISH JOURNAL OF CANCER | 2018年 / 119卷 / 06期

关键词：

CHOICE CHEMOTHERAPY; IPILIMUMAB; SURVIVAL; TRIAL;

D O I：

10.1038/s41416-018-0207-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), -002 (NCT01704287), and -006 (NCT01866319). METHODS: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed by independent central review per RECIST v1.1. RESULTS: 1567 patients were treated and 84 (5%) had mucosal melanoma. Fifty-one of 84 were ipilimumab-naive. In patients with mucosal melanoma, the objective response rate (ORR) was 19% (95% CI 11-29%), with median duration of response (DOR) of 27.6 months (range 1.1 + to 27.6). Median progression-free survival (PFS) was 2.8 months (95% CI 2.7-2.8), with median overall survival (OS) of 11.3 months (7.7-16.6). ORR was 22% (95% Cl 11-35%) and 15% (95% CI 5-32%) in ipilimumab-naive and ipilimumab-treated patients. CONCLUSION: Pembrolizumab provides durable antitumour activity in patients with advanced mucosal melanoma regardless of prior ipilimumab.

引用

页码：670 / 674

页数：5

共 12 条

[1]

Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO

[2]

2-G

[3] Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis [J].

D'Angelo, Sandra P. ;

Larkin, James ;

Sosman, Jeffrey A. ;

Lebbe, Celeste ;

Brady, Benjamin ;

Neyns, Bart ;

Schmidt, Henrik ;

Hassel, Jessica C. ;

Hodi, F. Stephen ;

Lorigan, Paul ;

Savage, Kerry J. ;

Miller, Wilson H., Jr. ;

Mohr, Peter ;

Marquez-Rodas, Ivan ;

Charles, Julie ;

Kaatz, Martin ;

Sznol, Mario ;

Weber, Jeffrey S. ;

Shoushtari, Alexander N. ;

Ruisi, Mary ;

Jiang, Joel ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) :226-+

[4] Whole-genome landscapes of major melanoma subtypes [J].

Hayward, Nicholas K. ;

Wilmott, James S. ;

Waddell, Nicola ;

Johansson, Peter A. ;

Field, Matthew A. ;

Nones, Katia ;

Patch, Ann-Marie ;

Kakavand, Hojabr ;

Alexandrov, Ludmil B. ;

Burke, Hazel ;

Jakrot, Valerie ;

Kazakoff, Stephen ;

Holmes, Oliver ;

Leonard, Conrad ;

Sabarinathan, Radhakrishnan ;

Mularoni, Loris ;

Wood, Scott ;

Xu, Qinying ;

Waddell, Nick ;

Tembe, Varsha ;

Pupo, Gulietta M. ;

De Paoli-Iseppi, Ricardo ;

Vilain, Ricardo E. ;

Shang, Ping ;

Lau, Loretta M. S. ;

Dagg, Rebecca A. ;

Schramm, Sarah-Jane ;

Pritchard, Antonia ;

Dutton-Regester, Ken ;

Newell, Felicity ;

Fitzgerald, Anna ;

Shang, Catherine A. ;

Grimmond, Sean M. ;

Pickett, Hilda A. ;

Yang, Jean Y. ;

Stretch, Jonathan R. ;

Behren, Andreas ;

Kefford, Richard F. ;

Hersey, Peter ;

Long, Georgina V. ;

Cebon, Jonathan ;

Shackleton, Mark ;

Spillane, Andrew J. ;

Saw, Robyn P. M. ;

Lopez-Bigas, Nuria ;

Pearson, John V. ;

Thompson, John F. ;

Scolyer, Richard A. ;

Mann, Graham J. .

NATURE, 2017, 545 (7653) :175-180

[5] Outcomes in Patients With Mucosal Melanomas [J].

Keller, Deborah S. ;

Thomay, Alan A. ;

Gaughan, John ;

Olszanski, Anthony ;

Wu, Hong ;

Berger, Adam C. ;

Farma, Jeffrey M. .

JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (08) :516-520

[6] Incidence of noncutaneous melanomas in the US [J].

McLaughlin, CC ;

Wu, XC ;

Jemal, A ;

Martin, HJ ;

Roche, LM ;

Chen, VW .

CANCER, 2005, 103 (05) :1000-1007

[7] Primary mucosal melanoma [J].

Patrick, Ronald J. ;

Fenske, Neil A. ;

Messina, Jane L. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (05) :828-834

[8] Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma [J].

Ribas, Antoni ;

Hamid, Omid ;

Daud, Adil ;

Hodi, F. Stephen ;

Wolchok, Jedd D. ;

Kefford, Richard ;

Joshua, Anthony M. ;

Patnaik, Amita ;

Hwu, Wen-Jen ;

Weber, Jeffrey S. ;

Gangadhar, Tara C. ;

Hersey, Peter ;

Dronca, Roxana ;

Joseph, Richard W. ;

Zarour, Hassane ;

Chmielowski, Bartosz ;

Lawrence, Donald P. ;

Algazi, Alain ;

Rizvi, Naiyer A. ;

Hoffner, Brianna ;

Mateus, Christine ;

Gergich, Kevin ;

Lindia, Jill A. ;

Giannotti, Maxine ;

Li, Xiaoyun Nicole ;

Ebbinghaus, Scot ;

Kang, S. Peter ;

Robert, Caroline .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (15) :1600-1609

[9] Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial [J].

Ribas, Antoni ;

Puzanov, Igor ;

Dummer, Reinhard ;

Schadendorf, Dirk ;

Hamid, Omid ;

Robert, Caroline ;

Hodi, F. Stephen ;

Schachter, Jacob ;

Pavlick, Anna C. ;

Lewis, Karl D. ;

Cranmer, Lee D. ;

Blank, Christian U. ;

O'Day, Steven J. ;

Ascierto, Paolo A. ;

Salama, April K. S. ;

Margolin, Kim A. ;

Loquai, Carmen ;

Eigentler, Thomas K. ;

Gangadhar, Tara C. ;

Carlino, Matteo S. ;

Agarwala, Sanjiv S. ;

Moschos, Stergios J. ;

Sosman, Jeffrey A. ;

Goldinger, Simone M. ;

Shapira-Frommer, Ronnie ;

Gonzalez, Rene ;

Kirkwood, John M. ;

Wolchok, Jedd D. ;

Eggermont, Alexander ;

Li, Xiaoyun Nicole ;

Zhou, Wei ;

Zernhelt, Adriane M. ;

Lis, Joy ;

Ebbinghaus, Scot ;

Kang, S. Peter ;

Daud, Adil .

LANCET ONCOLOGY, 2015, 16 (08) :908-918

[10] Pembrolizumab versus Ipilimumab in Advanced Melanoma [J].

Robert, Caroline ;

Schachter, Jacob ;

Long, Georgina V. ;

Arance, Ana ;

Grob, Jean Jacques ;

Mortier, Laurent ;

Daud, Adil ;

Carlino, Matteo S. ;

McNeil, Catriona ;

Lotem, Michal ;

Larkin, James ;

Lorigan, Paul ;

Neyns, Bart ;

Blank, Christian U. ;

Hamid, Omid ;

Mateus, Christine ;

Shapira-Frommer, Ronnie ;

Kosh, Michele ;

Zhou, Honghong ;

Ibrahim, Nageatte ;

Ebbinghaus, Scot ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2521-2532

← 1 2 →